DK2300474T3 - Spiro(piperidin-4,2'-pyrrolidin)-1-(3,5-trifluormethyl-phenyl)methylcarboxamider som nk1-tachikyninreceptor antagonister - Google Patents

Spiro(piperidin-4,2'-pyrrolidin)-1-(3,5-trifluormethyl-phenyl)methylcarboxamider som nk1-tachikyninreceptor antagonister

Info

Publication number
DK2300474T3
DK2300474T3 DK09738179.2T DK09738179T DK2300474T3 DK 2300474 T3 DK2300474 T3 DK 2300474T3 DK 09738179 T DK09738179 T DK 09738179T DK 2300474 T3 DK2300474 T3 DK 2300474T3
Authority
DK
Denmark
Prior art keywords
tachikynin
pyrrolidin
piperidin
spiro
trifluoromethyl
Prior art date
Application number
DK09738179.2T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Emiliano Castiglioni
Agostino Marasco
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Application granted granted Critical
Publication of DK2300474T3 publication Critical patent/DK2300474T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK09738179.2T 2008-05-01 2009-04-29 Spiro(piperidin-4,2'-pyrrolidin)-1-(3,5-trifluormethyl-phenyl)methylcarboxamider som nk1-tachikyninreceptor antagonister DK2300474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0808030.1A GB0808030D0 (en) 2008-05-01 2008-05-01 Novel compounds
PCT/EP2009/055190 WO2009133135A1 (en) 2008-05-01 2009-04-29 Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists

Publications (1)

Publication Number Publication Date
DK2300474T3 true DK2300474T3 (da) 2012-12-10

Family

ID=39537192

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09738179.2T DK2300474T3 (da) 2008-05-01 2009-04-29 Spiro(piperidin-4,2'-pyrrolidin)-1-(3,5-trifluormethyl-phenyl)methylcarboxamider som nk1-tachikyninreceptor antagonister

Country Status (22)

Country Link
US (2) US8367692B2 (da)
EP (1) EP2300474B1 (da)
JP (1) JP5524183B2 (da)
KR (1) KR101645743B1 (da)
CN (1) CN102083832B (da)
AU (1) AU2009242120B2 (da)
BR (1) BRPI0910530B8 (da)
CA (1) CA2723062C (da)
CY (1) CY1113458T1 (da)
DK (1) DK2300474T3 (da)
EA (1) EA017960B1 (da)
ES (1) ES2395571T3 (da)
GB (1) GB0808030D0 (da)
HR (1) HRP20121018T1 (da)
IL (1) IL208917A (da)
MX (1) MX2010011985A (da)
PL (1) PL2300474T3 (da)
PT (1) PT2300474E (da)
RS (1) RS52719B (da)
SI (1) SI2300474T1 (da)
WO (1) WO2009133135A1 (da)
ZA (1) ZA201007519B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484674A1 (en) * 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
CN109651368A (zh) * 2018-12-17 2019-04-19 武汉药明康德新药开发有限公司 4-甲酸甲酯-2-氧-1,8-二氮杂螺[4.5]癸烷-8-甲酸叔丁酯的制备方法
CN115697332A (zh) * 2020-06-02 2023-02-03 尼尔医疗有限公司 用于治疗由肺的机械损伤促进的肺纤维化状况的神经激肽(nk)-1受体拮抗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215706D0 (en) 1992-07-23 1992-09-09 Tollpass Limited Parking toll collecting system
EP0702681A1 (en) * 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin antagonists
JP2000514455A (ja) 1996-07-17 2000-10-31 メルク エンド カンパニー インコーポレーテッド タキキニンアンタゴニストによるサーカディアンリズムの改変
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
US7482365B2 (en) * 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP4389478B2 (ja) * 2002-05-29 2009-12-24 田辺三菱製薬株式会社 新規ピペリジン誘導体
JP4380508B2 (ja) * 2003-11-28 2009-12-09 田辺三菱製薬株式会社 医薬組成物
KR100877641B1 (ko) * 2003-11-28 2009-01-09 미쓰비시 타나베 파마 코퍼레이션 피페리딘 화합물 및 그의 제조 방법
JP2005154380A (ja) * 2003-11-28 2005-06-16 Tanabe Seiyaku Co Ltd ピペリジン誘導体
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20110053922A1 (en) 2011-03-03
PT2300474E (pt) 2013-01-07
RS52719B (en) 2013-08-30
IL208917A0 (en) 2011-01-31
JP5524183B2 (ja) 2014-06-18
SI2300474T1 (sl) 2013-01-31
CN102083832B (zh) 2013-06-05
AU2009242120B2 (en) 2012-05-24
BRPI0910530A2 (pt) 2015-08-18
CN102083832A (zh) 2011-06-01
EP2300474B1 (en) 2012-10-03
HRP20121018T1 (hr) 2013-01-31
KR20110015421A (ko) 2011-02-15
EP2300474A1 (en) 2011-03-30
PL2300474T3 (pl) 2013-03-29
GB0808030D0 (en) 2008-06-11
CA2723062A1 (en) 2009-11-05
EA201071259A1 (ru) 2011-10-31
ZA201007519B (en) 2011-11-30
AU2009242120A1 (en) 2009-11-05
ES2395571T3 (es) 2013-02-13
WO2009133135A1 (en) 2009-11-05
MX2010011985A (es) 2011-02-24
US8633214B2 (en) 2014-01-21
KR101645743B1 (ko) 2016-08-04
BRPI0910530B8 (pt) 2021-05-25
BRPI0910530B1 (pt) 2020-02-11
US8367692B2 (en) 2013-02-05
CA2723062C (en) 2016-07-05
EA017960B1 (ru) 2013-04-30
US20130123250A1 (en) 2013-05-16
IL208917A (en) 2014-06-30
JP2011518861A (ja) 2011-06-30
CY1113458T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
LTC1725537I2 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2094690T3 (da) 2-aza-bicyclo[3.1.0]hexanderivater som orexinreceptorantagonister
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
EP2349270A4 (en) 2,5-DISUBSTITUTED MORPHOLINE OREXIN RECEPTOR ANTAGONISTS
DK2225377T3 (da) Lna-antagonister, der er målrettet mod androgenreceptoren
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
EP2099454A4 (en) AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
IL212551A0 (en) Cxcr4 receptor compounds
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK2001876T3 (da) 8-Azabicyclo[3.2.1]octanforbindelser som mu-opioidreceptorantagonister
BRPI0912988A2 (pt) compostos bicíclicos tendo atividade no receptor cxcr4.
IL190686A0 (en) Il-21 receptor antagonists
SI2238110T1 (sl) Derivati 5,6-bisaril-2-piridin-karboksamida, njihova priprava in njihova terapevtska uporaba kot antagonisti receptorjev urotenzina II
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
DK2398780T3 (da) Cyclopropylamidderivater, som er målrettet mod histamin H3-receptoren
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
DK1912976T3 (da) Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister
AP2010005512A0 (en) Novel compounds active as muscarinic receptor antagonists.